This is a broad portfolio that includes all aspects of life sciences. Some of the representative areas are bioengineering (brain computer interface, chips to grow and monitor cellular activities, and bioprinting), vaccines and therapeutics (nanolipoprotein particles for the delivery of vaccines and drugs, carbon nanotubes for drug delivery, KRAS inhibitors, and anti-bacterial minerals), medical diagnostics (molecular diagnostics, point-of-care testing, imaging, and forensic), life science instrumentation (PCR instruments, rapid PCR, fluid partitioning, microfluidics, and biosensors), and methods for the extraction and purification of rare earth elements using lanmodulin and other natural/synthetic bacterial proteins.
Portfolio News and Multimedia
A Lawrence Livermore National Laboratory (LLNL) researcher and a colleague who helped him and his team commercialize their biomedical technology have garnered a national technology transfer award.
The award, from the Federal Laboratory Consortium (FLC), represents the 42nd technology transfer award that LLNL has won from the FLC since 1985.
Lawrence Livermore National Laboratory (LLNL) has joined forces with Precision Neuroscience Corporation (Precision) to advance the technology of neural implants for patients suffering from a variety of neurological disorders, including stroke, spinal cord injury and neurodegenerative diseases such as Lou Gehrig's disease.
Under the three-year collaboration, outlined in a Cooperative Research and Development Agreement (CRADA), LLNL scientists and engineers will work with Precision to develop future versions of the company’s neural implant – a thin-film microelectrode array called the Layer 7 Cortical Interface – with enhanced longevity.
The development of new antibiotics has stalled — new strategies are needed as the world enters the age of antibiotic resistance. To combat this challenge, Lawrence Livermore National Laboratory (LLNL) scientists have found that synthetic antibacterial minerals exhibit potent antibacterial activity against topical MRSA infections and increase the rate of wound closure.
A patent has been filed on this technology and Morrison’s research team is looking for industry partners to help commercialize this novel antimicrobial approach; click here for more information regarding partnership and licensing opportunities.
LLNL’s high throughput method involves proteome-wide screening for linear B-cell epitopes using native proteomes isolated from a pathogen of interest and convalescent sera from immunized animals. LLNL researchers have applied their newly developed generalizable screening method to the identification of pathogenic bacteria by screening linear B-cell epitopes in the proteome of Francisella…
LLNL has developed a novel process of production, isolation, characterization, and functional re-constitution of membrane-associated proteins in a single step. In addition, LLNL has developed a colorimetric assay that indicates production, correct folding, and incorporation of bR into soluble nanolipoprotein particles (NLPs).
LLNL has developed an approach, for formation of NLP/…